OncoLens
PrivateLast Round
Series B
Oct 24, 2024
Est. Valuation
$55M
Total Funding Raised
$27.1M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
OncoLens is a healthtech company that provides an AI-driven, oncology-focused digital health platform that enhances cancer care through analytics, multidisciplinary collaboration tools, and clinical trial matching.
Sector
Healthcare & Life Sciences
Verticals
EHR & EMR, Medical AI, Clinical Trials, Healthcare Analytics
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
OncoLens Comparables
Compare OncoLens with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Galen Health | 79% | |
| Health Catalyst | 77% | |
| Triomics | 77% |
OncoLens Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 24, 2024 | ||||
| Corporate Funding | Jul 13, 2023 | ||||
| Series A | Jan 14, 2021 | ||||
| Seed | Jan 7, 2020 | ||||
| Seed | Mar 26, 2019 |
Key People
Founding team and executive leadership
OncoLens Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BIP Capital | Series A, Seed, Series B |
| SeedtoB Capital | Series A, Series B |
| Cross Border Impact Ventures | Corporate Funding, Series B |
| Atlanta Technology Angels | Seed |
| Martin Ventures | Series A, Series B |
| Panoramic Ventures | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors grew 71% MoM, reaching 6.7K.
- May 19, 2025
Dr. Walter "Wally" Curran joins the Advisory Board.
OncoLens Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about OncoLens's valuation, stock price, and market status.
Is OncoLens a public or private company?
OncoLens is a private company.
What is the current stock price of OncoLens?
OncoLens is a private company, so its shares have no public market price. Caplight tracks OncoLens's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is OncoLens worth (valuation)?
OncoLens's valuation is estimated at $55.0M based on funding round data.
Can I buy OncoLens stock?
OncoLens shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was OncoLens's last funding round?
OncoLens's most recent funding round was Series B on October 24, 2024.
Who are the main investors in OncoLens?
Key investors in OncoLens include BIP Capital, Cross Border Impact Ventures, Atlanta Technology Angels, Panoramic Ventures.
Will OncoLens IPO soon?
No public IPO plans have been announced for OncoLens.
How can I track OncoLens secondary market activity?
Caplight tracks bids, offers, and trades in OncoLens's shares on secondary markets.